# Amgen Inc.  Share Price Target ‘$315.22’, now 1.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/amgen-inc-share-price-target-315-22-now-1-4-upside-potential/4121188108
- Published: 2025-03-05T12:28:17+00:00
- Author: Charlotte Edwards

**Amgen Inc.** which can be found using ticker (AMGN) have now 26 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between $389.00 and $185.00 calculating the mean target share
price we have $315.22. (at the time of writing). Given that the stocks previous 
close was at $310.78 this would indicate that there is a potential upside of 1.4%.
The 50 day moving average now sits at $281.02 and the 200 day MA is $306.02. The
company has a market cap of 167.71B. The current share price for the company is:
$312.19 USD

 The potential market cap would be $170,105,007,540 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 41.35, revenue per share of $62.24
and a 6.4% return on assets.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures
and delivers various human therapeutics. It operates in human therapeutics segment.
The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab),
Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha(
evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb),
Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO(
blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (
adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene
laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras,
Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment
of serious illness in the areas of inflammation, oncology/hematology, bone health,
cardiovascular disease, nephrology and neuroscience.

Share on:
